HAMPTON, N.J., May 17, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic melanoma and the Phase 1 dose-escalation study of varlilumab and nivolumab in multiple solid tumors, will be presented in oral presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago. Information in the abstracts is current as of the time of submission in February 2017.
  • Abstract #109: "A Phase 2 study of glembatumumab vedotin, an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma." Patrick A. Ott, M.D., Ph.D., Clinical Director of Dana-Farber Cancer Institute's Melanoma Center and its Center for Immuno-Oncology, and Assistant Professor of Medicine at Harvard Medical School, will present results during the Clinical Science Symposium "Hitting the Target: Antibody-Drug Conjugates," which begins on Monday, June 5, 2017 at 9:45 a.m. CDT.
  • Abstract #3007: "Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients." Rachel E. Sanborn, M.D., co-director of the Providence Thoracic Oncology Program at Providence Cancer Center in Portland, Ore., will present results during the session "Developmental Therapeutics—Immunotherapy," which begins on Monday, June 5, 2017 at 1:15 p.m. CDT.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Company ContactSarah CavanaughVice President of Investor Relations & Corp CommunicationsCelldex Therapeutics, Inc.(781) 433-3161scavanaugh@celldex.comCharles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 cliles@celldex.comMedia ContactDan BudwickFounder, 1AB Media(973) 271-6085 dan@1abmedia.com

Primary Logo